2 results match your criteria: "Huazhong University of Science and Technology. Electronic address: yinlei@whu.edu.cn.[Affiliation]"
Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases.
Int Immunopharmacol
September 2024
State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei Province 430072, China; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Electronic address:
Article Synopsis
- Cancer immunotherapies often fail in some patients because there's a lack of immune response, but dihydroartemisinin (DHA) has been found to induce a specific type of cell death that can trigger immune responses in liver cancer (HCC).
- DHA works by inhibiting certain proteins called cyclin-dependent kinases (CDKs), which increases reactive oxygen species (ROS) in cells, leading to this immune-activating cell death.
- In mouse studies, DHA not only increased the number of immune cells that attack tumors but also boosted the effectiveness of other cancer treatments like anti-PD-1 antibodies and CAR T-cell therapy, making it a promising treatment option for HCC patients.
Characterization of Autoantigen Presentation by HLA-C*06:02 in Psoriasis.
J Invest Dermatol
October 2017
State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, Department of Biochemistry and Molecular Biology, College of Life Sciences, Wuhan University, Wuhan, Hubei, China. Electronic address: